Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CHEK1 Gene Mutation Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
ATM Gene Mutation, ATR Gene Mutation, BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, FANCC Gene Mutation, FANCD2 Gene Mutation, FANCF Gene Mutation, FANCM Gene Mutation, NBN Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, RPA1 Gene Mutation, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
Other · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1151
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 713 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced May 21, 2026, 7:18 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CDK12 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, DNA Damage Response Gene Mutation, DNA Repair Gene Mutation, FANCA Gene Mutation, FANCD2 Gene Mutation, FANCL Gene Mutation, GEN1 Gene Mutation, NBN Gene Mutation, Prostate Carcinoma, RAD51 Gene Mutation, RAD51C Gene Mutation
Interventions
Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy
Drug · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 7:18 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC
Interventions
IDE-161, Pembrolizumab
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced May 21, 2026, 7:18 PM EDT